Akums Drugs & Pharma IPO: Public Issue Fully Subscribed On Day 1, GMP Hints Bumper Listing; Key Dates

The Initial Public Offering (IPO) of Akums Drugs and Pharmaceuticals Limited opened today. The mainboard IPO will remain open until 1st August 2024, providing a four-day window for investors to subscribe. With a price band fixed between Rs 646 to Rs 679 per equity share, the IPO has already garnered attention in the market, being nearly fully subscribed by 2:50 pm.

Key Details of Akums Drugs IPO

IPO Grey Market Premium (GMP): According to stock market observers, shares of Akums Drugs and Pharmaceuticals Limited are trading at a premium of Rs 181 in the grey market today. This indicates strong investor confidence and suggests that the shares could perform well upon listing.

IPO Price Band: The company has set the price band for its mainboard IPO at Rs 646 to Rs 679 per equity share. This pricing reflects the company's valuation and market positioning.

IPO Dates: The IPO opened today and will close on 1st August 2024.

IPO Size: Akums Drugs aims to raise Rs 1,856.74 crore through this IPO. Of this, Rs 1,176.74 crore is reserved for the Offer for Sale (OFS) route, allowing existing shareholders to sell their shares.

Lot Size: Investors can apply for the IPO in lots, with each lot comprising 22 shares.

Allotment Date: The share allocation after the IPO bidding closes is expected to be finalized on Friday, 2nd August 2024.

Registrar: Link Intime India Private Ltd has been appointed as the official registrar for the public issue.

Listing: The book build issue is proposed for listing on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE), providing liquidity and a wider market for the shares.

Listing Date: Following the 'T+3' listing rule, Akums Drugs is expected to list on the stock exchanges on Tuesday, 6th August 2024.

Subscription Status

As of 2:48 pm on the first day of bidding, the IPO has seen a healthy response. The book build issue has been subscribed 0.95 times overall, with the retail portion receiving 2.52 times subscription and the Non-Institutional Investors (NII) portion being booked 1.09 times.

Company Profile

Akums Drugs and Pharmaceuticals Limited is a player in the pharmaceutical industry, known for its products and manufacturing capabilities. The company has established a presence in the market, with a diverse product portfolio that includes formulations, nutraceuticals, and herbal products.

The IPO proceeds will primarily be used for general corporate purposes and to provide liquidity to existing shareholders through the Offer for Sale route. This move allows the company to strengthen its balance sheet while rewarding long-term shareholders. Moreover, the strong grey market premium suggests positive market sentiment and potential listing gains for investors.

As the IPO remains open for the next few days, potential investors should consider their options carefully. With the subscription already showing strong numbers, Akums Drugs and Pharmaceuticals IPO could be an opportunity for those looking to invest in the pharmaceutical sector.